Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report) have received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $63.50.
SUPN has been the subject of several recent research reports. Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the company an “overweight” rating in a research note on Wednesday. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Weiss Ratings downgraded shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Piper Sandler started coverage on Supernus Pharmaceuticals in a research note on Wednesday. They set an “overweight” rating and a $47.00 target price for the company. Finally, Jefferies Financial Group initiated coverage on Supernus Pharmaceuticals in a research note on Wednesday. They issued a “strong-buy” rating for the company.
View Our Latest Report on SUPN
Supernus Pharmaceuticals Stock Performance
SUPN opened at $26.16 on Friday. Supernus Pharmaceuticals has a 52-week low of $25.92 and a 52-week high of $42.81. The stock’s 50 day moving average price is $41.02 and its 200-day moving average price is $46.81. The stock has a market capitalization of $1.52 billion, a PE ratio of 7.31, a price-to-earnings-growth ratio of 1.19 and a beta of 0.52.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). Supernus Pharmaceuticals had a negative net margin of 5.07% and a positive return on equity of 12.99%. The firm had revenue of $208.60 million for the quarter, compared to the consensus estimate of $217.56 million. During the same period in the previous year, the business posted ($0.80) earnings per share. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. Research analysts forecast that Supernus Pharmaceuticals will post 3.15 EPS for the current fiscal year.
Supernus Pharmaceuticals Dividend Announcement
The business also recently declared a special dividend, which was paid on Friday, November 6th. Investors of record on Friday, October 30th were given a dividend of $8.13 per share.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SUPN. Public Employees Retirement System of Ohio bought a new position in Supernus Pharmaceuticals during the second quarter worth $25,000. Rockefeller Capital Management L.P. lifted its holdings in Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares in the last quarter. Heritage Family Offices LLP bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter valued at $39,000. Global Retirement Partners LLC bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at approximately $64,000. Finally, Versant Capital Management Inc boosted its holdings in shares of Supernus Pharmaceuticals by 47.2% during the third quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock worth $65,000 after purchasing an additional 482 shares during the period. Hedge funds and other institutional investors own 60.33% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.
Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.
Featured Stories
- Five stocks we like better than Supernus Pharmaceuticals
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
